Galectin Therapeutics, Inc. announced that it will present top-line results from the NAVIGATE trial regarding its drug belapectin for patients with MASH cirrhosis and portal hypertension at the 2025 ...
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing ...
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases ...
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding ...
The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results